详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

A miRNA-mediated attenuation of hepatocarcinogenesis in both hepatocytes and Kupffer cells

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 预警期刊

作者：

机构： [1]Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan,China [2]Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of HopeNational Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA [3]Department of Immuno-oncology, Beckman Research Institute, City of Hope NationalMedical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA [4]Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, ZhejiangUniversity, 3 East Qingchun Road, Hangzhou, Zhejiang 310016, China [5]Graduate School of Biological Science, City of Hope National Medical Center, Duarte, CA91010, USA

出处：

DOI：

ISSN：

摘要：

MicroRNAs (miRNAs) are small noncoding RNAs that regulate a variety of physiological and pathological functions. miR-26a is one of the many miRNAs that have been identified as regulators of cancer development and as potential anticancer drug targets. However, the specific cellular and molecular mechanisms by which miR-26a attenuates hepatocarcinogenesis are still elusive. Here, we interrogated mouse models with miR-26a cell-specific overexpression in either hepatocytes or myeloid cells to show that miR-26a strongly attenuated the chemical-induced hepatocellular carcinoma (HCC). miR-26a overexpression broadly inhibited the inflammatory response in both hepatocytes and macrophages by decreasing several key oncogenic signaling pathways in HCC promotion. These findings thus reveal new insights into a concerted role of miR-26a in both hepatocytes and Kupffer cells to suppress hepatocarcinogenesis, thereby highlighting the potential use of miR-26a mimetics as potential approaches for the prevention and treatment of HCC.© 2022 The Author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区医学：研究与实验

最新[2023]版：

大类 | 2 区

医学

小类 | 2 区医学：研究与实验

第一作者：

第一作者机构： [1]Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan,China [2]Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of HopeNational Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA

共同第一作者：

通讯作者：

通讯机构： [1]Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan,China [2]Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of HopeNational Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA [5]Graduate School of Biological Science, City of Hope National Medical Center, Duarte, CA91010, USA [*1]Division of Endocrinology and Metabolism, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China. [*2]Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA 91010, USA.

推荐引用方式(GB/T 7714)：

APA：

MLA：